GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LabTurbo Biotech Corp (ROCO:7725) » Definitions » Operating Income

LabTurbo Biotech (ROCO:7725) Operating Income : NT$-182.51 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is LabTurbo Biotech Operating Income?

LabTurbo Biotech's Operating Income for the six months ended in Dec. 2024 was NT$-96.59 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-182.51 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. LabTurbo Biotech's Operating Income for the six months ended in Dec. 2024 was NT$-96.59 Mil. LabTurbo Biotech's Revenue for the six months ended in Dec. 2024 was NT$31.91 Mil. Therefore, LabTurbo Biotech's Operating Margin % for the quarter that ended in Dec. 2024 was -302.71%.

LabTurbo Biotech's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LabTurbo Biotech's annualized ROC % for the quarter that ended in Dec. 2024 was -39.21%. LabTurbo Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -49.71%.


LabTurbo Biotech Operating Income Historical Data

The historical data trend for LabTurbo Biotech's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LabTurbo Biotech Operating Income Chart

LabTurbo Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Operating Income
584.20 798.39 -178.75 -182.51

LabTurbo Biotech Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Operating Income Get a 7-Day Free Trial 98.66 -69.10 -109.65 -85.93 -96.59

LabTurbo Biotech Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-182.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LabTurbo Biotech  (ROCO:7725) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LabTurbo Biotech's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-193.17 * ( 1 - 0.05% )/( (511.238 + 473.533)/ 2 )
=-193.073415/492.3855
=-39.21 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1389.589 - 29.611 - ( 886.445 - max(0, 48.374 - 1003.151+886.445))
=473.533

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

LabTurbo Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-144.392/( ( (239.755 + max(45.515, 0)) + (227.161 + max(68.515, 0)) )/ 2 )
=-144.392/( ( 285.27 + 295.676 )/ 2 )
=-144.392/290.473
=-49.71 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.861 + 70.79 + 23.742) - (52.903 + 0 + 6.975)
=45.515

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8.77 + 98.498 + 3.0829999999999) - (29.611 + 0 + 12.225)
=68.515

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

LabTurbo Biotech's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-96.585/31.907
=-302.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


LabTurbo Biotech Operating Income Related Terms

Thank you for viewing the detailed overview of LabTurbo Biotech's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


LabTurbo Biotech Business Description

Traded in Other Exchanges
N/A
Address
3F-1, No. 150, Section 4, Chengde Road, Shilin District, Taipei, TWN
LabTurbo Biotech Corp is a company that is mainly engaged in the research and development, production, sales of nucleic acid extraction, genetic testing, genetic testing reagents, instruments, and the operation of sports science venues. Its main products and services include the entire process. Automated precision medical genetic testing systems and reagent kits as well as testing services.

LabTurbo Biotech Headlines

No Headlines